CX-4945 (Silmitasertib), ATP-competitive CK2 protein kinase inhibitor (ab141350)

Overview

  • Product name

    CX-4945 (Silmitasertib), ATP-competitive CK2 protein kinase inhibitor
  • Description

    Potent, selective ATP-competitive CK2 protein kinase inhibitor
  • Alternative names

    • Silmitasertib
  • Biological description

    Potent, selective ATP-competitive CK2 protein kinase inhibitor (IC50 = 1 nM, CK2α). Shows broad spectrum antiproliferative effects. Inhibits human umbilical vein endothelial cell migration, tube formation and HIF-1α in cancer cells. Shows antitumor effects in vivo. Orally active.
  • Purity

    > 95%
  • CAS Number

    1009820-21-6
  • Chemical structure

    Chemical Structure

Properties

References

This product has been referenced in:

  • Lu H  et al. CK2 phosphorylates and inhibits TAp73 tumor suppressor function to promote expression of cancer stem cell genes and phenotype in head and neck cancer. Neoplasia 16:789-800 (2014). Read more (PubMed: 25379016) »
  • Siddiqui-Jain A  et al. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther 11:994-1005 (2012). Read more (PubMed: 22267551) »
  • Siddiqui-Jain A  et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 70:10288-98 (2010). Read more (PubMed: 21159648) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab141350.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up